Table 1.
Clinical features of Covid-19 SCI cohort.
| Variable | Sample (N = 7) |
|---|---|
| Age—median (IQR) year | 68 (34–75) |
| Male sex—No./total No. (%) | 5/7 (71.4) |
| SCI level | |
| Cervical (number/sample (%)) | 5/7 (71.4) |
| Thoracic T1-T6 (number/sample (%)) | 1/7 (14.3) |
| Thoracic T7-T12 (number/sample (%)) | 1/7 (14.3) |
| Lumbosacral (number/sample (%)) | 0/7 (0) |
| SCI etiology | |
| Traumatic (number/sample (%)) | 4/7 (57.1) |
| Vascular (number/sample (%)) | 2/7 (28.6) |
| Iatrogenic (number/sample (%)) | 1/7 (14.3) |
| AIS Impairment Scale | |
| A (number/sample (%)) | 4/7 (57.1) |
| B (number/sample (%)) | 0/7 (0) |
| C (number/sample (%)) | 2/7 (28.6) |
| D (number/sample (%)) | 1/7 (14.3) |
| E (number/sample (%)) | 0/7 (0) |
| Tracheostomy (number/sample (%)) | 4/7 (57.1) |
| Need to remove respiratory secretions (number/sample (%)) | 2/4 (50) |
| Contact with Covid-19 patient (number/sample (%)) | 2/7 (28.6) |
| Incubation period—media (IQR) dias | 6.5 (4–9) |
| History of smoking (current or former) (number/sample (%)) | 3/7 (42.9) |
| Coexisting disorders (number/sample (%)) | |
| Any | 0 (0) |
| Hypertension | 4 (57.1) |
| Diabetes | 1 (14.3) |
| Dyslipidemia | 4 (57.1) |
| Obesity | 3 (42.9) |
| Cardiovascular disease | 3 (42.9) |
| Pulmonary disease | 3 (42.9) |
| Chronic renal disease | 0 (0) |
| Cancer | 1 (14.3) |
| Symptoms of Covid-19 onset (number/sample (%)) | |
| Fever | 6 (85.7) |
| Dyspnea | 3 (42.9) |
| Cough | 3 (42.9) |
| Fatigue | 4 (57.1) |
| Sputum production | 3 (42.9) |
| Confusion | 2 (28.6) |
| Gastrointestinal symptoms | 1 (14.3) |
| Modified Early Warning System (MEWS) | |
| 0–2 points(number/sample (%) | 2/7 (28.6) |
| >3 points (number/sample (%) | 5/7 (71.4) |
| CURB-65—if pneumonia | |
| 0–1 points (number/sample (%) | 1/5 (20) |
| >1 points (number/sample (%) | 4/5 (80) |